Efficacy
The efficacy of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation was prospectively assessed in patients with SCLC. Median length of survival was 12.5 months and 11.8 months, respectively, for patients treated with cisplatin/etoposide and carboplatin/etoposide, with no statistically significant difference. Both combinations were equally effective in tumour response and survival.
Tumour response and survival between cisplatin/etoposide and carboplatin/etoposider
Outcomer
|
Cisplatin/etoposide |
Carboplatin/etoposide |
Limited Disease (n=41) |
Extensive Disease (n=30) |
Limited Disease (n=41) |
Extensive Disease (n=31) |
Complete response
n (%) 95% CI |
18 (44%)
28%-49% |
3 (10%)
0-20 % |
15 (37%)
22%51% |
5 (16%)
3%-29% |
Partial response
n (%) |
12 (29%) |
12 (40%) |
20 (49%) |
15 (48%) |
Overall response
n (%)
95%CI
|
30 (73%)
10%-43%
|
15 (50%)
22%-57%
|
35 (86%)
33%-64%
|
20 (64%)
3%-66%
|
Stable disease
n (%) |
6 (15%) |
10 (33%) |
2 (5%) |
7 (23%) |
Progressive disease (n) |
1 |
2 |
3 |
3 |
Non evaluable patients (n) |
4 |
3 |
1 |
1 |
Median time to progression (range) |
8.4 months (1-35 months) |
8.6 months (1-57 months) |
Median survival |
12.5 months |
11.8 months |
Based on the results of the meta analysis,r median overall survival was equivalent for patients with limited stage disease receiving cisplatin-based therapy compared with carboplatin-based therapy (p=0.17) as was median progression free survival (p=0.57).
© J Clin Oncol 2012